August 26th 2025
Where to find members of our editorial board at this year's European Society of Retina Specialists Congress
Antibiotics do not lower Avastin infection risk
August 18th 2008The incidence of endophthalmitis is independent of whether prophylactic antibiotics are administered in conjunction with Avastin (bevacizumab) injections, according to results of a study published in the February 2008 issue of Spektrum der Augenheilkunde.
VEGF-A levels in RP and non-RP eyes
August 11th 2008Sufferers of retinitis pigmentosa (RP) have a lower concentration of vascular endothelial growth factor A (VEGF-A) in the aqueous humour than non-sufferers, according to results of a study published in the August 2008 issue of Investigative Ophthalmology and Visual Science.
Nutraceutical helps patient see clearly
July 14th 2008Longevinex (Resveratrol), a nutraceutical matrix, can remove lipofuscin deposits from the retina to improve visual acuity and night vision, according to research presented at this year's meeting of the American Academy of Optometry in Seattle, US.
Wet AMD sufferers unaware of pre-existing AMD
July 14th 2008Current screening of patients with age-related macular degeneration (AMD) does not sufficiently identify those patients most at risk of wet AMD and hence is unable to prevent its development, according to a report published in the June 2008 issue of Eye.
Low dose Medidur FA safe and effective in DME
July 8th 2008Low doses of Alimera Sciences' Medidur FA provide visual acuity improvements and reduce the risk of ocular side effects commonly associated with corticosteroids, when administered to diabetic macular oedema (DME) patients, according to the three-month interim results of the first human pharmacokinetic (PK) study.
Enzyme therapy could replace surgical vitrectomy
July 8th 2008ThromboGenics' experimental enzyme therapy, microplasmin, has been shown to induce a posterior vitreous detachment (PVD) in over 30% of patients in the high dose group, without the need for surgical intervention, according to the results of the Phase IIb MIVI III (Microplasmin for Vitreous Injection) trial.
Surgery may help improve vision when anti-VEGF therapy ineffective
June 25th 2008Surgical therapy for age-related macular degeneration in the form of macular translocation, injection of tissue plasminogen activator, and gas tamponade provides some improvements in visual acuity for patients whose conditions do not respond to the anti-vascular endothelial growth factor drugs.
Fundus autofluorescence imaging betters armamentarium
June 25th 2008Fundus autofluorescence imaging, one of the modes available in a new instrument (Spectralis HRA+OCT, Heidelberg Engineering), enhances its utility as a diagnostic device and a tool for monitoring therapy of patients with retinal and macular diseases.
Model predicts advanced AMD development
June 18th 2008A new model can predict the percentage of people who will develop advanced age-related macular degeneration (AMD) at various ages. The model, which is based on well-established risk factors for the disease such as age, smoking, and genetics, considers high-risk, intermediate-risk, and low-risk genotypes. Genotypes are more predictive of the risk of developing advanced AMD than is age.